Gene Therapy for Primary Immunodeficiencies
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
For over 40 years, primary immunodeficiencies (PIDs) have featured prominently in the development and refinement of human allogeneic hematopoietic stem cell transplantation. More recently, ex vivo somatic gene therapy using autologous cells has provided remarkable evidence of clinical efficacy in patients without HLA-matched stem cell donors and in whom toxicity of allogeneic procedures is likely to be high. Together with improved preclinical models, a wealth of information has accumulated that has allowed development of safer, more sophisticated technologies and protocols that are applicable to a much broader range of diseases. In this review we summarize the status of these gene therapy trials and discuss the emerging application of similar strategies to other PIDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“Regrettably (and surprisingly at the time), 2 to 6 years after treatment five patients who were clinically well developed T-cell acute lymphoblastic leukemia (T-ALL) resulting from mutagenic retroviral insertions (Hacein-Bey-Abina et al., 2008; Howe et al., 2008).”
BackgroundLombardo, A., Genovese, P., Beausejour, C. M., Colleoni, S., Lee, Y.-L., Kim, K. A., Ando, D., Urnov, F. D., Galli, C., Gregory, P. D., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1353 · Cited by 845
Stem-Cell Gene Therapy for the Wiskott–Aldrich Syndrome
Boztug, K., Schmidt, M., Schwarzer, A., Banerjee, P. P., Díez, I. A., Dewey, R. A., Böhm, M., Nowrouzi, A., Ball, C. R., Glimm, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003548 · Cited by 532
Retrovirus and lentivirus vector design and methods of cell conditioning
Cooray, S., Howe, S. J., & Thrasher, A. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00003-x · Cited by 65 · cited 1×
“Stem cell culture conditions and transduction protocols have also been improved to enhance cell viability and gene transfer efficiency during ex vivo procedures (Cooray et al., 2012).”
BackgroundSelf-citation
Cited by
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Kaufmann, K. B., Büning, H., Galy, A., Schambach, A., & Grez, M. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202287 · Cited by 276
BET proteins promote efficient murine leukemia virus integration at transcription start sites
Sharma, A., Larue, R. C., Plumb, M. R., Malani, N., Male, F., Slaughter, A., Kessl, J. J., Shkriabai, N., Coward, E., Aiyer, S. S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307157110 · Cited by 193
Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor
Wang, X., Olszewska, M., Qu, J., Wasielewska, T., Bartido, S., Hermetet, G., Sadelain, M., & Rivière, I. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000072 · Cited by 70
Genetic medicines for CF: Hype versus reality
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A., et al. (2016) · Pediatric Pulmonology · doi:10.1002/ppul.23543 · Cited by 53
Bimodal high-affinity association of Brd4 with murine leukemia virus integrase and mononucleosomes
Larue, R. C., Plumb, M. R., Crowe, B. L., Shkriabai, N., Sharma, A., DiFiore, J., Malani, N., Aiyer, S. S., Roth, M. J., Bushman, F. D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku135 · Cited by 44
Metadata
- Authors
- Rivat, C., Santilli, G., Gaspar, H. B., & Thrasher, A. J.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2012-07
- Volume
- 23
- Issue
- 7
- Pages
- 668-675
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W3022092663
- Cited by
- 60
- References
- 4
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.